Trial Profile
A Phase Ib/II Trial of Ipilimumab-Nivolumab-Denosumab and Nivolumab-Denosumab in Patients With Unresectable Stage III and IV Melanoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 05 Jul 2023
Price :
$35
*
At a glance
- Drugs Denosumab (Primary) ; Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions; Therapeutic Use
- Acronyms CHARLI
- 06 Jun 2023 Results (n=27) presented at the 59th Annual Meeting of the American Society of Clinical Oncology
- 06 Apr 2022 Status changed from recruiting to active, no longer recruiting.
- 23 Mar 2021 Planned End Date changed from 30 Jun 2023 to 1 Dec 2023.